Sarilumab单药对比阿达木单抗单药治疗活动性类风湿关节炎的III期MONARCH试验
MONARCH是一项随机、双盲、双模拟、活性对照的III期优效性试验,比较Sarilumab 200 mg每2周与阿达木单抗40 mg每2周单药治疗24周,纳入因不耐受或应答不佳而不能继续甲氨蝶呤的活动性类风湿关节炎患者。结果显示Sarilumab在DAS28-ESR较基线变化上优于阿达木单抗(-3.28 vs -2.20;p<0.0001),ACR20/50/70应答率均更高,安全性与预期类别效应一致。
要点
- Sarilumab单药在DAS28-ESR改善上优于阿达木单抗单药(-3.28 vs -2.20;p<0.0001)。
- Sarilumab组ACR20/50/70应答率均显著高于阿达木单抗组(p≤0.0074)。
- 两组不良事件发生率相近,感染及严重感染发生率相似。
核心结论
- 对于不能继续甲氨蝶呤治疗的活动性类风湿关节炎患者,Sarilumab单药在改善症状体征和躯体功能方面优于阿达木单抗单药。
- 两种治疗的安全性特征与预期类别效应一致。
研究设计与样本
- MONARCH为随机、活性对照、双盲、双模拟、III期优效性试验(NCT02332590)。
- 患者接受Sarilumab 200 mg每2周或阿达木单抗40 mg每2周单药治疗24周。
- 主要终点为第24周DAS28-ESR较基线的变化。
主要发现
- Sarilumab在主要终点DAS28-ESR较基线变化上优于阿达木单抗(-3.28 vs -2.20;p<0.0001)。
- Sarilumab组ACR20/50/70应答率分别为71.7%/45.7%/23.4%,阿达木单抗组为58.4%/29.7%/11.9%(均p≤0.0074)。
- Sarilumab组HAQ-DI改善显著更优(p=0.0037)。
- 第24周Sarilumab组CDAI缓解率7.1% vs 2.7%(名义p=0.0468),低疾病活动度41.8% vs 24.9%(名义p=0.0005,补充分析)。
- 不良事件发生率阿达木单抗63.6%、Sarilumab 64.1%;常见不良事件Sarilumab组为中性粒细胞减少和注射部位反应,阿达木单抗组为头痛和RA加重。
关键数值与推荐
- 感染发生率Sarilumab 28.8%、阿达木单抗27.7%;严重感染两组均为1.1%。
临床怎么用
- 对于因不耐受或应答不佳而不能继续甲氨蝶呤的活动性RA患者,Sarilumab单药可作为优于阿达木单抗单药的治疗选择。
- 使用Sarilumab单药时需关注中性粒细胞减少和注射部位反应,但感染风险与阿达木单抗单药相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare efficacy and safety of sarilumab monotherapy with adalimumab monotherapy in patients with active rheumatoid arthritis (RA) who should not continue treatment with methotrexate (MTX) due to intolerance or inadequate response. METHODS: MONARCH was a randomised, active-controlled, double-blind, double-dummy, phase III superiority trial. Patients received sarilumab (200 mg every 2 weeks (q2w)) or adalimumab (40 mg q2w) monotherapy for 24 weeks. The primary end point was change from baseline in 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) at week 24. RESULTS: Sarilumab was superior to adalimumab in the primary end point of change from baseline in DAS28-ESR (-3.28 vs -2.20; p<0.0001). Sarilumab-treated patients achieved significantly higher American College of Rheumatology 20/50/70 response rates (sarilumab: 71.7%/45.7%/23.4%; adalimumab: 58.4%/29.7%/11.9%; all p≤0.0074) and had significantly greater improvement in Health Assessment Questionnaire-Disability Index (p=0.0037). Importantly, at week 24, more patients receiving sarilumab compared with adalimumab achieved Clinical Disease Activity Index remission (7.1% vs 2.7%; nominal p=0.0468) and low disease activity (41.8% vs 24.9%; nominal p=0.0005, supplemental analysis). Adverse events occurred in 63.6% (adalimumab) and 64.1% (sarilumab) of patients, the most common being neutropenia and injection site reactions (sarilumab) and headache and worsening RA (adalimumab). Incidences of infections (sarilumab: 28.8%; adalimumab: 27.7%) and serious infections (1.1%, both groups) were similar, despite neutropenia differences. CONCLUSIONS: Sarilumab monotherapy demonstrated superiority to adalimumab monotherapy by improving the signs and symptoms and physical functions in patients with RA who were unable to continue MTX treatment. The safety profiles of both therapies were consistent with anticipated class effects. TRIAL REGISTRATION NUMBER: NCT02332590.
引用
- Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2016. PMID: 27856432. doi:10.1136/annrheumdis-2016-210310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。